Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

Cancer Letters

Volumn 365, Issue 1, 2015, Pages 23-29

  Teng, Feifei ^a   Kong, Li ^a   Meng, Xiangjiao ^a   Yang, Jia ^a   Yu, Jinming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cancer treatment; Checkpoint; CTLA 4; Immunotherapy; PD L1; Radiotherapy

Indexed keywords

AMINOTRANSFERASE; CD134 ANTIBODY; CD137 ANTIBODY; CD40 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; MONOCLONAL ANTIBODY; PEMBROLIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLITIS; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; ESOPHAGITIS; FATIGUE; GLIOMA; HEPATITIS; HUMAN; HYPOPHYSITIS; IRIDOCYCLITIS; LEUKOPENIA; LUNG CANCER; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRITIS; NEUROPATHY; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIATION RESPONSE; RASH; SHORT SURVEY; SIDE EFFECT; STEREOTACTIC BODY RADIATION THERAPY; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; ADVERSE EFFECTS; ANIMAL; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMORADIOTHERAPY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHEMORADIOTHERAPY; DOSE FRACTIONATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84930822709     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.012     Document Type: Review

References (55)

1. Rupnow B.A., Knox S.J. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis 1999, 4:115-143.
2. Wasserman J., Blomgren H., Rotstein S., Petrini B., Hammarstrom S. Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors. Bull. N. Y. Acad. Med 1989, 65:36-44.
3. Finkelstein S.E., Timmerman R., McBride W.H., Schaue D., Hoffe S.E., Mantz C.A., et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin. Dev. Immunol 2011, 2011:439752.
4. Hatzi V.I., Laskaratou D.A., Mavragani I.V., Nikitaki Z., Mangelis A., Panayiotidis M.I., et al. Non-targeted radiation effects in vivo: a critical glance of the future in radiobiology. Cancer Lett 2015, 356:34-42.
5. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med 2012, 366:925-931.
6. Dovedi S.J., Adlard A.L., Lipowska-Bhalla G., McKenna C., Jones S., Cheadle E.J., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014, 74:5458-5468.
7. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst 2013, 105:256-265.
8. Deng L., Liang H., Burnette B., Beckett M., Darga T., Weichselbaum R.R., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest 2014, 124:687-695.
9. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res 2013, 1:365-372.
10. Son C.H., Bae J.H., Shin D.Y., Lee H.R., Choi Y.J., Jo W.S., et al. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. J. Immunother 2014, 37:1-7.
11. Berzofsky J.A., Terabe M., Wood L.V. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin. Oncol 2012, 39:348-357.
12. Melero I., Grimaldi A.M., Perez-Gracia J.L., Ascierto P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res 2013, 19:997-1008.
13. Sharabi A.B., Nirschl C.J., Kochel C.M., Nirschl T.R., Francica B.J., Velarde E., et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. Res 2015, 3:345-355.
14. Twyman-Saint Victor C., Rech A.J., Maity A., Rengan R., Pauken K.E., Stelekati E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520(7547):373-377.
15. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med 2010, 363:711-723.
16. Callahan M.K., Wolchok J.D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol 2013, 94:41-53.
17. Basu G.D., Ghazalpour A., Pockaj B.A. e.a., Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys 2014, 90. (Suppl.); S1-S2.
18. Stamell E.F., Wolchok J.D., Gnjatic S., Lee N.Y., Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys 2013, 85:293-295.
19. Grimaldi A.M., Simeone E., Giannarelli D., Muto P., Falivene S., Borzillo V., et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014, 3:e28780.
20. Kwon E.D., Drake C.G., Scher H.I., Fizazi K., Bossi A., van den Eertwegh A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15:700-712.
21. Honeychurch J., Glennie M.J., Johnson P.W., Illidge T.M. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003, 102:1449-1457.
22. Demaria S., Kawashima N., Yang A.M., Devitt M.L., Babb J.S., Allison J.P., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res 2005, 11:728-734.
23. Shi W., Siemann D.W. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res 2006, 26:3445-3453.
24. Yokouchi H., Yamazaki K., Chamoto K., Kikuchi E., Shinagawa N., Oizumi S., et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci 2008, 99:361-367.
25. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med 2009, 206:3015-3029.
26. Newcomb E.W., Lukyanov Y., Kawashima N., Alonso-Basanta M., Wang S.C., Liu M., et al. Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat. Res 2010, 173:426-432.
27. Zeng J., See A.P., Phallen J., Jackson C.M., Belcaid Z., Ruzevick J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys 2013, 86:343-349.
28. Verbrugge I., Hagekyriakou J., Sharp L.L., Galli M., West A., McLaughlin N.M., et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012, 72:3163-3174.
29. Rodel F., Frey B., Gaipl U., Keilholz L., Fournier C., Manda K., et al. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr. Med. Chem 2012, 19:1741-1750.
30. Sharma A., Bode B., Wenger R.H., Lehmann K., Sartori A.A., Moch H., et al. Gamma-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE 2011, 6:e28217.
31. Schaue D., Ratikan J.A., Iwamoto K.S., McBride W.H. Maximizing tumor immunity with fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys 2012, 83:1306-1310.
32. Sharabi A.B., Nirschl C.J., Kochel C.M., Nirschl T.R., Francica B.J., Velarde E., et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol. Res 2015, 3:345-355.
33. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
34. Tsai M.H., Cook J.A., Chandramouli G.V., DeGraff W., Yan H., Zhao S., et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 2007, 67:3845-3852.
35. Antwih D.A., Gabbara K.M., Lancaster W.D., Ruden D.M., Zielske S.P. Radiation-induced epigenetic DNA methylation modification of radiation-response pathways. Epigenetics 2013, 8:839-848.
36. Halvorsen A.R., Helland A., Fleischer T., Haug K.M., Grenaker Alnaes G.I., Nebdal D., et al. Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy. Int. J. Cancer 2014, 135:2085-2095.
37. Lisowska H., Deperas-Kaminska M., Haghdoost S., Parmryd I., Wojcik A. Radiation-induced DNA damage and repair in human gammadelta and alphabeta T-lymphocytes analysed by the alkaline comet assay. Genome Integrity 2010, 1:8.
38. Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res 2009, 15:5379-5388.
39. Vonderheide R.H., LoRusso P.M., Khalil M., Gartner E.M., Khaira D., Soulieres D., et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res 2010, 16:3485-3494.
40. Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest 2009, 119:551-564.
41. Bradley J.D., Paulus R., Komaki R., Masters G., Blumenschein G., Schild S., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015, 16:187-199.
42. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
43. Huang Y., Liao H., Zhang Y., Yuan R., Wang F., Gao Y., et al. Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS ONE 2014, 9:e94376.
44. Kong X., Sun R., Chen Y., Wei H., Tian Z. GammadeltaT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. J. Immunol 2014, 193:1645-1653.
45. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 2012, 366:2443-2454.
46. Berman D., Wolchok J.D., Weber J., Hamid O., O'Day S., Chasalow S. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J. Clin. Oncol 2009, 27. suppl;abstr 3020.
47. Callahan M.K., Wolchok J.D., Allison J.P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol 2010, 37:473-484.
48. Ascierto P.A., Kalos M., Schaer D.A., Callahan M.K., Wolchok J.D. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin. Cancer Res 2013, 19:1009-1020.
49. Wang W., Yu D., Sarnaik A.A., Yu B., Hall M., Morelli D., et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J. Transl. Med 2012, 10:146.
50. Kitano S., Postow M.A., Cortez C., Rasalan T., Gallardo H.F., Panageas K., et al. Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10 mg/kg to predict for overall survival in patients with metastatic melanoma. J. Clin. Oncol 2012, 30. (suppl; abstr 2518).
51. Agassi A.M., Myslicki F.A., Shulman J.M., Rotterman Y., Dosoretz D.E., Fernandez E., et al. The promise of combining radiation therapy and immunotherapy: morbidity and toxicity. Future Oncol 2014, 10:2319-2328.
52. Brahmer J.R. e.a., 2013 ASCO Annual Meeting. J. Clin. Oncol 2013, 31. (suppl; abstr 8030).
53. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
54. Weber J.S., O'Day S., Urba W., Powderly J., Nichol G., Yellin M., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol 2008, 26:5950-5956.
55. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbe C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res 2009, 15:7412-7420.